Alpha Cognition Inc Alpha Cognition Inc

Alpha Cognition Inc

ACOG

Rang în acțiuni #20188
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Preț acțiune
$8.47
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$131.47M
Schimbare (1 zi)
3.36%
Schimbare (1 an)
68.29%
Țară
US
Tranzacționează Alpha Cognition Inc (ACOG)

Categorie

Healthcare
Raport P/B pentru Alpha Cognition Inc (ACOG)
Raport P/B la data de October 2026 TTM: -114.63
Conform celor mai recente rapoarte financiare și prețului acțiunilor Alpha Cognition Inc, raportul P/B actual (TTM) este -114.63. La sfârșitul anului 2022, compania avea un P/B de -274.94.
Istoricul raportului P/B pentru Alpha Cognition Inc din 2018 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
2026 (TTM) -114.63 -53.90%
2023 -248.67 -9.55%
2022 -274.94 -288.08%
2021 146.19 -97.93%
2020 7.05K 6,164.26%
2019 112.47 16.25%
2018 96.75 0.00%
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
6.251 -105.45%
US
13.2547 -111.56%
US
4.208 -103.67%
AU
- -
CH
6.1824 -105.39%
NL